» Articles » PMID: 21738819

Mammalian Target of Rapamycin: a Central Node of Complex Signaling Cascades

Overview
Specialty Pathology
Date 2011 Jul 9
PMID 21738819
Citations 57
Authors
Affiliations
Soon will be listed here.
Abstract

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates cell growth and metabolism in response to diverse external stimuli. In the presence of mitogenic stimuli, mTOR transduces signals that activate the translational machinery and promote cell growth. mTOR functions as a central node in a complex net of signaling pathways that are involved both in normal physiological, as well as pathogenic events. mTOR signaling occurs in concert with upstream Akt and tuberous sclerosis complex (TSC) and several downstream effectors. During the past few decades, the mTOR-mediated pathway has been shown to promote tumorigenesis through the coordinated phosphorylation of proteins that directly regulate cell-cycle progression and metabolism, as well as transcription factors that regulate the expression of genes involved in the oncogenic processes. The importance of mTOR signaling in oncology is now widely accepted, and agents that selectively target mTOR have been developed as anti-cancer drugs. In this review, we highlight the past research on mTOR, including clinical and pathological analyses, and describe its molecular mechanisms of signaling, and its roles in the physiology and pathology of human diseases, particularly, lung carcinomas. We also discuss strategies that might lead to more effective clinical treatments of several diseases by targeting mTOR.

Citing Articles

mTORC1, the maestro of cell metabolism and growth.

He L, Cho S, Blenis J Genes Dev. 2024; 39(1-2):109-131.

PMID: 39572234 PMC: 11789495. DOI: 10.1101/gad.352084.124.


mTOR hyperactivity and amplification as targets for personalized treatments in malignancies.

Sztankovics D, Moldvai D, Petovari G, Danko T, Szalai F, Miyaura R Pathol Oncol Res. 2024; 30:1611643.

PMID: 38515456 PMC: 10954904. DOI: 10.3389/pore.2024.1611643.


The first Iranian patient with You-Hoover-Fong syndrome and a review of the literature on 27 cases: expanding the genotypic and phenotypic spectrum.

Shokrollahi N, Tehrani Fateh S, Nouri M, Behnam A, Moghimi P, Sadeghi H Neurol Sci. 2024; 45(8):3979-3987.

PMID: 38421525 DOI: 10.1007/s10072-024-07413-y.


Implication of mTOR Signaling in NSCLC: Mechanisms and Therapeutic Perspectives.

Gargalionis A, Papavassiliou K, Papavassiliou A Cells. 2023; 12(15).

PMID: 37566093 PMC: 10416991. DOI: 10.3390/cells12152014.


FERM domain-containing protein FRMD6 activates the mTOR signaling pathway and promotes lung cancer progression.

Wang T, Guo H, Zhang L, Yu M, Li Q, Zhang J Front Med. 2023; 17(4):714-728.

PMID: 37060526 DOI: 10.1007/s11684-022-0959-5.


References
1.
Balsara B, Pei J, Mitsuuchi Y, Page R, Klein-Szanto A, Wang H . Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions. Carcinogenesis. 2004; 25(11):2053-9. DOI: 10.1093/carcin/bgh226. View

2.
Wong A, Kim S, Leung P, Auersperg N, Pelech S . Profiling of protein kinases in the neoplastic transformation of human ovarian surface epithelium. Gynecol Oncol. 2001; 82(2):305-11. DOI: 10.1006/gyno.2001.6280. View

3.
Vega F, Medeiros L, Leventaki V, Atwell C, Cho-Vega J, Tian L . Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. Cancer Res. 2006; 66(13):6589-97. PMC: 4839264. DOI: 10.1158/0008-5472.CAN-05-3018. View

4.
Dobashi Y, Suzuki S, Sato E, Hamada Y, Yanagawa T, Ooi A . EGFR-dependent and independent activation of Akt/mTOR cascade in bone and soft tissue tumors. Mod Pathol. 2009; 22(10):1328-40. DOI: 10.1038/modpathol.2009.104. View

5.
Atkins M, Hidalgo M, Stadler W, Logan T, Dutcher J, Hudes G . Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol. 2004; 22(5):909-18. DOI: 10.1200/JCO.2004.08.185. View